* Gliatech Inc., of Cleveland, Ohio, said it receivedEuropean Union regulatory approval for marketing of itsAdcon-L for prevention of post-operative scarring andadhesions following lumbar surgery. Adcon (short foradhesion control) is a semisynthetic carbohydratepolymeric gel.
* Human Genome Sciences Inc., of Rockville, Md., saidits chairman and CEO, William Haseltine, was a co-recipient with former First Lady Nancy Reagan of anannual award from the New York-based Carter BurdenFoundation for the Aging for contributions tounderstanding health problems of older people.
* Interneuron Pharmaceuticals Inc., of Lexington, Mass.,signed an agreement with Ingelheim, Germany-basedBoehringer Ingelheim GmbH for manufacturing ofdexfenfluramine, which is under review by the FDA forobesity. Interneuron said it will provide the activeingredient for the drug, whose brand name is Redux, toBoehringer Ingelheim, which will produce the capsules.Redux will be sold in the U.S. by Interneuron's marketingpartner, American Home Products, of Madison, N.J. Thedrug was recommended for approval Nov. 16, 1995, bythe FDA's Endocrinologic and Metabolic Drugs AdvisoryCommittee.
* Teva Pharmaceutical Industries Ltd., of Jerusalem,completed its $25 million acquisition of a 78 percentinterest in Hungary-based Biogal Pharmaceu-tical Co.Ltd.
(c) 1997 American Health Consultants. All rights reserved.